文献速递胃肠动力与功能性疾病

综述:肠易激综合征与其他肠脑互动障碍的流行病学

Review article: epidemiology of IBS and other bowel disorders of gut-brain interaction (DGBI).
PubMed 文献 · Aliment Pharmacol Ther · 2021-01-01

肠脑互动障碍(DGBI)累及全消化道,按解剖区域分为食管、胃十二指肠、肠道和肛门直肠四类。肠易激综合征(IBS)是研究最多的肠道DGBI,其患病率调查受缺乏生物标志物、诊断标准繁多及方法学异质性三大障碍影响。本文旨在梳理IBS流行病学认识,并为2026年将发布的Rome V标准前的流行病学研究提出改进策略。

要点

  • IBS患病率估计依赖诊断标准,缺乏生物标志物是核心障碍。
  • 多年、多标准、多方法、多人群研究汇总的单一患病率难以解读。
  • 患病率对疾病负担评估、资源分配和新疗法优先排序具有重要意义。

核心结论

  • IBS患病率研究受缺乏生物标志物、诊断标准繁多和方法学异质性三大障碍影响,汇总不同研究得到的单一患病率难以解读其可靠性和意义。

研究设计与样本

  • 综述,未报告系统检索范围,旨在梳理IBS在DGBI背景下的流行病学认识并提出改进流行病学研究的策略。

主要发现

  • DGBI通常按食管、胃十二指肠、肠道和肛门直肠四个主要解剖区域分类。
  • IBS是研究最多的肠道DGBI,已有大量流行病学研究。
  • 将长期、不同诊断标准、不同方法学和不同研究人群的多项研究结果汇总为单一患病率时,结果难以解读。

局限性

  • 原文指出IBS患病率研究存在缺乏生物标志物、诊断标准繁多和方法学异质性三大障碍。
  • 原文指出汇总不同诊断标准、不同方法学和不同研究人群的多项研究结果来确定单一患病率时,结果难以解读且可靠性难以确定,这一缺陷未被充分认识。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The disorders of gut-brain interactions (DGBI) are a spectrum of gastrointestinal (GI) disorders that involve the entire GI tract and are usually categorised into four major anatomic GI regions, oesophageal, gastroduodenal, bowel and anorectal. Irritable bowel syndrome (IBS), a bowel DGBI, is one of the most researched DGBI and has been the subject of copious epidemiological studies. Prevalence rates are based on diagnostic criteria. In the case of IBS, there are three central obstacles to attaining a clear picture of prevalence: the absence of biomarkers, the multitude of diagnostic criteria used over the years, and the heterogeneous nature of the methodology used in epidemiologic surveys. When the results of multiple studies, conducted over a long period of time, using different diagnostic criteria and different research methodology, and involving different study populations are pooled to determine a single summary prevalence rate it is difficult to interpret the results and to determine their reliability and significance. This pitfall is insufficiently recognised and unfortunate because prevalence rates are important for understanding the burden of disease, for allocating healthcare and research resources, and for incentivising and prioritising new treatments. The aims of the present paper are to highlight our knowledge and understanding of IBS epidemiology within the context of other DGBI, and to present strategies to improve epidemiological research, especially in advance of the new Rome V criteria, to be published in 2026.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Sperber AD. Review article: epidemiology of IBS and other bowel disorders of gut-brain interaction (DGBI). Aliment Pharmacol Ther. 2021. PMID: 34927754. doi:10.1111/apt.16582

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。